This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Felcisetrag
- DrugBank Accession Number
- DB12725
- Background
Felcisetrag (TD-8954) has been used in trials studying the treatment of Enteral Feeding Intolerance and Gastrointestinal Motility Disorder.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Felcisetrag (DB12725)
- Weight
- Average: 455.603
Monoisotopic: 455.289640071 - Chemical Formula
- C25H37N5O3
- Synonyms
- Felcisetrag
- External IDs
- TAK-954
- TD-8954
- THRX-149699
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The risk or severity of adverse effects can be increased when 1,2-Benzodiazepine is combined with TD-8954. Acenocoumarol The risk or severity of adverse effects can be increased when TD-8954 is combined with Acenocoumarol. Acetazolamide The risk or severity of adverse effects can be increased when Acetazolamide is combined with TD-8954. Acetophenazine The risk or severity of adverse effects can be increased when Acetophenazine is combined with TD-8954. Agomelatine The risk or severity of adverse effects can be increased when Agomelatine is combined with TD-8954. Alfentanil The risk or severity of adverse effects can be increased when Alfentanil is combined with TD-8954. Alimemazine The risk or severity of adverse effects can be increased when Alimemazine is combined with TD-8954. Almotriptan The risk or severity of adverse effects can be increased when Almotriptan is combined with TD-8954. Alosetron The risk or severity of adverse effects can be increased when Alosetron is combined with TD-8954. Alprazolam The risk or severity of adverse effects can be increased when Alprazolam is combined with TD-8954. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as benzimidazoles. These are organic compounds containing a benzene ring fused to an imidazole ring (five member ring containing a nitrogen atom, 4 carbon atoms, and two double bonds).
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Benzimidazoles
- Sub Class
- Not Available
- Direct Parent
- Benzimidazoles
- Alternative Parents
- Piperidinecarboxylic acids / Benzenoids / Methylcarbamates / Imidazoles / Heteroaromatic compounds / Trialkylamines / Secondary carboxylic acid amides / Azacyclic compounds / Organic oxides / Hydrocarbon derivatives show 1 more
- Substituents
- Amine / Amino acid or derivatives / Aromatic heteropolycyclic compound / Azacycle / Azole / Benzenoid / Benzimidazole / Carbamic acid ester / Carbonyl group / Carboxamide group show 15 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 35F0Y2W16Q
- CAS number
- 916075-84-8
- InChI Key
- MZOITCJKGUIQEI-UHFFFAOYSA-N
- InChI
- InChI=1S/C25H37N5O3/c1-17(2)23-27-21-6-4-5-20(22(21)28-23)24(31)26-15-18-7-11-29(12-8-18)16-19-9-13-30(14-10-19)25(32)33-3/h4-6,17-19H,7-16H2,1-3H3,(H,26,31)(H,27,28)
- IUPAC Name
- methyl 4-{[4-({[2-(propan-2-yl)-1H-1,3-benzodiazol-7-yl]formamido}methyl)piperidin-1-yl]methyl}piperidine-1-carboxylate
- SMILES
- COC(=O)N1CCC(CN2CCC(CNC(=O)C3=C4NC(=NC4=CC=C3)C(C)C)CC2)CC1
References
- General References
- Not Available
- External Links
- PubChem Compound
- 11961293
- PubChem Substance
- 347828920
- ChemSpider
- 10135539
- BindingDB
- 50436989
- ChEMBL
- CHEMBL2402904
- ZINC
- ZINC000043150989
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Coronavirus Disease 2019 (COVID‑19) / Postoperative Gastrointestinal Dysfunction 1 2 Completed Treatment Diabetic Gastroparesis / Idiopathic Gastroparesis 1 2 Terminated Treatment Critically Ill Patients / Enteral Feeding Intolerance (EFI) / Nutrition, Enteral 1 1 Completed Other Healthy Subjects (HS) 3 1 Completed Other Healthy Subjects (HS) / Hepatic Impairment 1 1 Completed Other Healthy Subjects (HS) / Impaired Renal Function 1 1 Terminated Other Upper gastrointestinal motility disorders 1 1, 2 Completed Treatment Enteral Feeding Intolerance (EFI) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0518 mg/mL ALOGPS logP 3.69 ALOGPS logP 2.26 Chemaxon logS -3.9 ALOGPS pKa (Strongest Acidic) 10.75 Chemaxon pKa (Strongest Basic) 9.77 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 90.56 Å2 Chemaxon Rotatable Bond Count 7 Chemaxon Refractivity 129.02 m3·mol-1 Chemaxon Polarizability 52.73 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created at October 20, 2016 23:50 / Updated at August 13, 2021 04:44